NXTCL"s selection algorithm is based on a number of functional assays that examine the ability of stem cells to affect immune cells and secrete specific proteins in response to various stimuli. The selection algorithm is used to give an overall assessment of the cells" ability and to select only those cells that have the desired effect.

NXTCL"s drug candidate, ProTrans, consists of selected stem cells from several pooled donors. Treatment with ProTrans has been shown to be a safe treatment at all doses evaluated and is now being evaluated for efficacy in the ongoing phase II clinical trial, ProTrans-1.

“This sale shows the possibility of obtaining revenue from the selection algorithm, long before ProTrans can be subject to market authorization. The ongoing clinical trial has certainly put us on the map and shown that our cells are safe to use in humans,” says Mathias Svahn, CEO of NextCell. 

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Leo Groenewegen, CFO

Phone: 08-735 5595

E-mail: info@nextcellpharma.com

www.nextcellpharma.com

About NextCell Pharma AB:

Stem cells are expected to change the way how many of today"s life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB"s proprietary method. In addition, the company has a service called Cellaviva, Sweden"s first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.